Skip to main content
. Author manuscript; available in PMC: 2019 Aug 11.
Published in final edited form as: Nat Med. 2019 Feb 11;25(3):477–486. doi: 10.1038/s41591-018-0337-7

Fig. 5. RNAseq comparison to TCGA.

Fig. 5

We combined our RNAseq dataset with that of TCGA glioblastoma dataset with appropriate batch correction to estimate the fraction of glioblastoma patients with positive enrichment of the cell cycle/cancer proliferation signatures (GSVA score ≥ 0.2). Three out of 14 tumors in the neoadjuvant group demonstrated positive enrichment while there were 11 of 15 tumors in the adjuvant group and 73 of 166 tumors in The Cancer Genome Atlas set. TCGA: The Cancer Genome Atlas. GSVA: gene set variation analysis.